Molecular Docking study, and In vitro Evaluation of Antitumor Activity of Some New Isoxazoline and Pyrazoline Derivatives of Nabumetone against breast cancer cell line (MCF-7)

A variety of new pyrazolines, isoxazolines, and amide derivatives were designed, synthesized, tested in vitro for their cytotoxic potential against the breast cancer cell line MCF-7. Nabumetone is a prodrug that used as non-steroidal anti-inflammatory drug
 
 (NSAID). Before synthesis, Molecular docking program (GOLD suite v. 5.7.1) was to evaluate selectivity ER-α receptor, which demonstrated good agreement with findings. Specifically, compounds 1e 2e target ER- α receptor had greatest PLP fitness values (75.61 73.36), respectively, when compared tamoxifen reference medication, (92.78). The IC50 synthesized revealed compound (1e) has high value 19 µM MCF-7, tamoxifen, an (18.02) µM.